机译:卡马汀或洛莫司汀与贝伐单抗的回顾性研究在先前贝伐单抗治疗失败的复发性胶质母细胞瘤患者中
Harvard Medical School, Boston, Massachusetts;
Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts;
Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;
Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;
Boston University School of Medicine, Boston, Massachusetts;
Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;
Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts,Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts,Dana Farber Cancer Institute, Center for Neuro-Oncology, 450 Brookline Avenue, D-2110, Boston, MA 02115;
bevacizumab; malignant glioma; nitrosoureas; recurrent glioblastoma;
机译:复发性胶质母细胞瘤患者随机分配贝伐单抗加洛莫司汀,贝伐单抗单药或洛莫司汀单药对循环内皮细胞的预后价值和动力学。荷兰神经肿瘤学集团BELOB试验的报告
机译:复发性胶质母细胞瘤患者的单药贝伐单抗或洛莫司汀与贝伐单抗加洛莫司汀联用(BELOB试验):一项随机对照2期试验
机译:最后行贝伐单抗与贝伐单抗/洛米汀治疗的多形胶质母细胞瘤复发患者的无进展生存期和总生存期
机译:利用扩散和灌注成像预测胶质母细胞瘤对贝伐单抗治疗的响应
机译:长春新碱,伊非替康,替莫唑胺和贝伐单抗(VIT-B)逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
机译:卡马汀或洛莫司汀与贝伐单抗的回顾性研究在先前贝伐单抗治疗失败的复发性胶质母细胞瘤患者中
机译:复发性胶质母细胞瘤患者随机分配贝伐单抗加洛莫司汀,贝伐单抗单药或洛莫司汀单药对循环内皮细胞的预后价值和动力学。荷兰神经肿瘤学集团BELOB试验的报告